We turn new chemical classes from nature into high-value products with real-world impact
We are currently discovering and developing the next generation of antimicrobials
Septoria (wheat)
Septoria
(wheat)
Wheat constitutes 20%
of the world’s nutrient intake
Septoria destroys up to 50%
of a farmer’s yield
20% of the global nutrient intake comes from wheat
Septoria destroys up to 50% of a farmer’s yield
Aspergillosis
Aspergillosis
1.8M deaths per year
30%-50% mortality rates when treated
1.8M deaths
per year
30% - 50% mortality
rates when treated
Gram negatives
Gram
negatives
3 million deaths per year
Biggest threat to modern hospitals
3 million deaths per year
Biggest threat
to modern hospitals
1 compound
2 compounds
4 compounds
Novel
class
In vitro
testing
In planta
testing
Scale-up &
formulation
Small
field trials
Novel class
In vitro testing
In planta testing
Scale-up & formulation
Small field trials
$3.1 Bn
Market size
12
Compounds
RESULTS
Our 3 leading programmes will make the world safer and greener
SEPTORIA
Protecting the global food supply with natural fungicides
Wheat constitutes 20% of the global calorie intake but is under threat from the fungal disease Septoria
Farmers lose up to 50% of their yield, with increasing resistance to current fungicides
Bactobio has discovered multiple new fungicidal classes that are effective, safe, and bypass resistance
We are testing the most developed new classes on the field and expect to create market-leading products that help protect the world’s food supply
ASPERGILLOSIS
Next-generation antifungals: combating aspergillosis
Invasive Aspergillosis is a rapidly progressing, highly lethal fungal infection that threatens the lives of immunocompromised patients worldwide
No new antifungal class has been brought to market in 20 years and rising resistance means that patients now often die even when treated
We are advancing a vital new line of defense. We have identified several novel antimicrobial classes with >99% in vitro efficacy and low early toxicity
Our new classes have the potential to protect millions of patients’ lives worldwide
Stewardship: There is no stewardship for Aspergillosis, meaning our new medications would be part of the defence of most patients from day 1
GRAM NEGATIVES
New classes and synergies to treat Gram-negative infections
Drug-resistant Gram-negative bacteria often target immune-compromised patients, especially in hospitals
Gram Negatives are deadly and our clinical arsenal is failing with no therapeutic breakthroughs in the last 30 years
We have discovered a new antibiotic class that is highly effective, looks safe, and works in synergy with the antibiotic of last resort, colistin
Our new class has the potential to save the lives of millions, while also protecting our healthcare system
Stewardship: Infections are often chronic or so deadly that stewardship would not be appropriate, meaning our new medications would be large contributors from day 1
If you want to work with us please